AI Article Synopsis
- The study investigates the causal relationship between polymyalgia rheumatica (PMR) and giant cell arteritis (GCA), two autoimmune diseases that often occur together.
- Researchers utilized Mendelian randomization (MR) and SNP data from the FinnGen Biobank to identify connections between the two diseases.
- Findings suggest that GCA increases the risk of PMR and vice versa, indicating a significant causal relationship, highlighting the importance of managing PMR in patients with GCA and suggesting potential new treatments.
Article Abstract
Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) as 2 types of autoimmune diseases are frequently concomitant, and Mendelian randomization (MR) was applied in this study to assess the causal relationship between them. In this study, single-nucleotide polymorphism (SNP) was used as the instrumental variable for Mendelian analysis, and the SNP data of GCA and PMR were obtained from the FinnGen Biobank databases. SNPs are significantly correlated with GCA and PMR and were screened based on preset thresholds. Inverse variance weighted analysis was used as the main analysis, supplemented with MR-Egger and weighted median. The evidence of the impact of GCA on PMR risk was found in inverse variance weighted results (odds ratio, 1.22 [95% confidence interval, 1.11-1.34]; P < .01), and the evidence of the impact of PMR on GCA risk has also been found (odds ratio, 1.58 [95% confidence interval, 1.28-1.96]; P < .01). Finally, the stability and reliability of the results were tested using the retention method, heterogeneity test, and horizontal gene pleiotropy test. MR analysis indicates that GCA increases the risk of PMR and PMR is an important risk factor for GCA, with a causal relationship. The potential value of reasonable management of PMR in patients with GCA has received high attention. In addition, novel GCA therapeutics may be indicated for PMR, and it is a potential for further investigation.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11419444 | PMC |
| http://dx.doi.org/10.1097/MD.0000000000039723 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Different giant cell arteritis phenotypes may present distinct types of ischaemic complications.
Clin Exp Rheumatol
December 2024
Department of Rheumatology, Hospital Universitario La Paz, Madrid, Spain.
Objectives: To determine if the subtype of vascular ultrasound (US) presentation is associated with different types of ischaemic complications (IC) in giant cell arteritis (GCA).
Methods: Retrospective observational analysis of GCA clinically confirmed patients referred to US fast-track clinics at two centres. All patients underwent baseline US of cranial and extracranial arteries (carotid, subclavian and axillary).
Infective agents and polymyalgia rheumatica: key discussion points emerging from a narrative review of published literature.
Reumatologia
November 2024
Department of Primary Care, Health District of Soverato, Azienda Sanitaria Provinciale Catanzaro, Italy.
Introduction: The aetiology of polymyalgia rheumatica (PMR) is unknown. Recently, reports on cases of PMR following the coronavirus disease 2019 (COVID-19) have revived the role of infection as an aetiological or triggering factor. It is estimated that patients with PMR have manifestations of giant cell arteritis (GCA) in < 20% of cases.
View Article and Find Full Text PDFBaricitinib in polymyalgia rheumatica and giant cell arteritis: report of six cases.
Reumatismo
October 2024
Division of Rheumatology, "La Colletta" Hospital, Azienda Sociosanitaria Ligure 3, Arenzano.
Article Synopsis
- This case series evaluates the effectiveness and safety of baricitinib (BARI) in treating six patients suffering from polymyalgia rheumatica (PMR) and giant cell arteritis (GCA), particularly when traditional treatments like tocilizumab were unavailable.
- Patients showed significant improvement in symptoms, with a notable reduction in their disease activity scores and the ability of some to discontinue glucocorticoids while on BARI.
- Overall, the findings align with previous studies indicating that Janus kinase inhibitors may serve as a helpful alternative for managing PMR and GCA by reducing reliance on glucocorticoids, although one patient did experience pneumonia after treatment.
Purpose Of Review: There have been advances in the diagnosis and treatment of giant cell arteritis (GCA) and polymyalgia rheumatica (PMR).
Recent Findings: Themes in PMR and GCA include classification criteria, ultrasound imaging of temporal and axillary arteries replacing biopsies for diagnosis of GCA, faster diagnosis and treatment with rapid access clinics for suspected GCA, and expanding treatment options with the goal of rapid suppression of inflammation and sparing steroids.
Summary: Treatment is aimed at suppressing inflammation quickly in both GCA and PMR.
Temporal artery biopsy in giant cell arteritis: clinical perspectives and histological patterns.
Front Med (Lausanne)
September 2024
Rheumatology, Department of Clinical Sciences, Lund University, Lund, Sweden.
Although its role has been debated, temporal artery biopsy (TAB) remains the gold standard for the diagnosis of cranial giant cell arteritis (GCA). The specificity of TAB is excellent and the sensitivity, albeit lower, is comparable with other diagnostic modalities used for the diagnosis of GCA. This outpatient procedure has a low rate of complications and is well integrated in the majority of healthcare systems.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!